Department of Endocrinology, C. I. Parhon Institute of Endocrinology, Carol Davila University of Medicine and Pharmacy, 011863 Bucharest, Romania.
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Genes (Basel). 2024 Sep 1;15(9):1152. doi: 10.3390/genes15091152.
The Fat Mass and Obesity-Associated () gene encodes a demethylase, which modulates RNA N6-methyladenosine (m6A) and plays a regulatory role in adipocyte differentiation and the pathogenesis of human obesity.
To understand the potential role of in osteoporosis (OP), we investigated five single nucleotide variations (SNVs) in intron 1 (rs8057044, rs8050136, rs9939609, rs62033406, and rs9930506) of the gene, and a missense SNV i.e., rs3736228 (A1330V), located in exon 18 of the gene, in a cohort of postmenopausal women ( = 188) from Central Europe. Genotyping was performed with an allele discrimination assay, while haplotypes were reconstructed in the population by PHASE 2.1.
The rs9930506 was strongly associated with OP ( < 0.0035), which was supported by Bonferroni correction ( < 0.0175), and all SNVs located in the gene were more strongly associated with severe OP with fragility fractures. Among seventeen haplotypes detected for the gene, two haplotypes (H1 and H9) were frequent (frequency > 10%) and distributed in three main haplotypes pairs (H1/H1, H1/H9 and H9/H9, respectively). The pathogenic pair H1/H9 was associated with a leaner phenotype, increased fracture risk, and a lower bone mineral density (BMD), and carried the heterozygous GA of rs9930506, while the protective pair H9/H9 was associated with an increased obesity risk and carried AA alleles of rs9939609.
Concordant associations with OP, an increased fracture risk, and a lower BMD at all skeletal sites indicate that the gene is a promising candidate for OP, explaining the complex relationship with obesity and offering new perspectives for the study of the epigenetic regulation of bone metabolism.
脂肪量和肥胖相关(FTO)基因编码一种去甲基酶,可调节 RNA N6-甲基腺苷(m6A),并在脂肪细胞分化和人类肥胖症的发病机制中发挥调节作用。
为了了解 FTO 基因在骨质疏松症(OP)中的潜在作用,我们研究了位于该基因内含子 1 中的 5 个单核苷酸变异(SNV)(rs8057044、rs8050136、rs9939609、rs62033406 和 rs9930506)和外显子 18 中的错义 SNV(rs3736228,A1330V)在中欧地区的一组绝经后妇女(= 188)中。通过等位基因区分分析进行基因分型,而通过 PHASE 2.1 在人群中重建单体型。
rs9930506 与 OP 强烈相关(<0.0035),经 Bonferroni 校正后仍具有统计学意义(<0.0175),且位于 FTO 基因中的所有 SNV 与伴有脆性骨折的严重 OP 相关性更强。在所检测到的 FTO 基因的 17 种单体型中,两种单体型(H1 和 H9)较为常见(频率>10%),分布在三个主要单体型对(H1/H1、H1/H9 和 H9/H9)中。致病单体型对 H1/H9 与较瘦的表型、骨折风险增加和较低的骨密度(BMD)相关,并携带 rs9930506 的杂合性 GA,而保护性单体型对 H9/H9 与肥胖风险增加相关,并携带 rs9939609 的 AA 等位基因。
与 OP、骨折风险增加和所有骨骼部位的 BMD 降低相一致的关联表明,FTO 基因是 OP 的一个有希望的候选基因,解释了其与肥胖的复杂关系,并为骨代谢的表观遗传调控研究提供了新的视角。